ORIGINAL RESEARCH article

Front. Oncol.

Sec. Molecular and Cellular Oncology

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1592616

RBP7 knockdown inhibits proliferation of human hepatocellular carcinoma and activates the p38 MAPK pathway

Provisionally accepted
Jinhai  LiJinhai Li1,2*HUawei  ZhaiHUawei Zhai2Fujing  CaiFujing Cai2Xian  ZhangXian Zhang3Yu  ZhouYu Zhou2Maolin  YanMaolin Yan1,4Huachun  SunHuachun Sun1Haifeng  ZhangHaifeng Zhang1Guangzheng  SunGuangzheng Sun2Minghui  ZhuMinghui Zhu2Jing  YuanJing Yuan5Ningxin  ZhangNingxin Zhang3Maolin  YanMaolin Yan1
  • 1Shengli Clinical Medical College, Fujian Medical University, Fuzhou, China
  • 2Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China
  • 3Wenzhou Medical University, Wenzhou, Zhejiang Province, China
  • 4Affiliated Hospital of Guilin Medical University, Guilin, Guangxi Zhuang Region, China
  • 5Zhenjiang Hospital of Integrated Traditional Chinese and Western Medicine, Zhenjiang, Jiangsu Province, China

The final, formatted version of the article will be published soon.

Background: Retinoid metabolism is critical for maintaining liver homeostasis, and its dysregulation is closely associated with liver diseases. Retinol binding protein 7 (RBP7) involves in retinoids transport, particularly in liver, indicating its importance in hepatic functions. However, its specific role in hepatocellular carcinoma (HCC) tumorigenesis remains unclear and needs to further investigation.Methods: Bioinformatics was employed to assess RBP7 expression across different cohorts.The expression level of RBP7 in cells were further validated using qRT-PCR and western blot. Additionally, we investigated the impact of RBP7 knockdown on cell cycle-related genes, apoptosis-related proteins, and p38 MAPK signaling activity. Functional assays, including CCK8, colony formation, flow cytometry (FACS) analysis, Annexin V/7-AAD staining and xenograft tumor assay, were performed to determine the vitro and in vivo role of RBP7. Survival analysis was conducted to evaluate the correlation between RBP7 expression and the prognosis of HCC patients.Results: RBP7 is frequently elevated in HCC tumor tissues, particularly in early-stage patients. Notably, high RBP7 expression is closely correlated with overall survival (OS) and disease-specific survival (DSS) in HCC patients. Knockdown of RBP7 inhibited cell proliferation in vitro and suppressed tumor growth in vivo by inducing cell cycle arrest and apoptosis. Mechanistically, we found that RBP7 knockdown-induced suppression of HCC cell proliferation was associated with increased phosphorylation of p38 MAPK.4 Conclusion: Our findings demonstrate that RBP7 suppression activates p38 MAPK signaling pathway, leading to impaired cell proliferation. These results suggest that RBP7 may serve as both a prognostic biomarker and a promising therapeutic target for HCC.

Keywords: RBP7 suppression inhibits HCC proliferation via activating p38 cell proliferation, Hepatocellular Carcinoma, p38, MAPK, RBP7, Retinoid

Received: 13 Mar 2025; Accepted: 09 Jun 2025.

Copyright: © 2025 Li, Zhai, Cai, Zhang, Zhou, Yan, Sun, Zhang, Sun, Zhu, Yuan, Zhang and Yan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Jinhai Li, Shengli Clinical Medical College, Fujian Medical University, Fuzhou, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.